1. Female Thai patients aged between 20 and 60 years 2. Body mass index (BMI) between 22 and 26 kg/m2 tirzepatide, body contouring, microwave device
Conditions
Interventions
Participants will first be evaluated for eligibility by the study physician through medical history taking and physical examination. Those who pass the initial screening will undergo laboratory invest
Experimental Device
Tirzepatide with microwave device
Sponsors
Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Eligibility
Sex/Gender
Female
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Female Thai patients aged between 20 and 60 years 2. Body mass index (BMI) between 22 and 26 kg/m2
Exclusion criteria
Exclusion criteria: 1. Participants who are pregnant or breastfeeding. 2. Participants with serious underlying diseases, such as cancer, liver failure, renal failure, tumors, thyroid disorders, cardiovascular diseases, or coagulation disorders. 3. Participants with severe gastrointestinal diseases, such as pancreatitis, intestinal obstruction, intestinal ischemia, gallstones, etc. 4. Participants with a history of type 1 or type 2 diabetes mellitus. 5. Participants with a family history (first or second-degree relatives) of thyroid cancer or Multiple Endocrine Neoplasia Type 2 (MEN2). 6. Participants with a history of hypersensitivity to tirzepatide. 7. Participants who have used hormonal therapy or oral contraceptives within the past 3 months. 8. Participants who have undergone a barium swallow examination or received contrast media within the past 1 month. 9. Participants with metal implants in the body, hip or spinal prostheses, or cardiac pacemakers. 10. Participants who are unable to lie still or remain in a supine position. 11. Participants with a history of bariatric surgery. 12. Participants who have received treatment for localized fat reduction within the past 1 year, such as weight-loss medications, laser therapy, radiofrequency, ultrasound, or cryolipolysis. 13. Participants who have undergone surgery or experienced bone fractures in the trunk area within the past 1 year. 14. Participants with diagnosed psychiatric disorders confirmed by a psychiatrist. 15. Participants with skin diseases at the treatment site, such as dermatitis, infected wounds, etc. 16. Participants who do not consent to clinical photography for treatment evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fat percentage Baseline, 1wk, 12 wks, 24 wks after treatment DEXA scan,Weight wk 0,1,2,3,4,5,6,7,8,9,10,11,12,16,20,24,28,32,36 Weighing machine,Waist circumference wk 0,1,2,3,4,5,6,7,8,9,10,11,12,16,20,24,28,32,36 Measuring tape,Hip circumference wk 0,1,2,3,4,5,6,7,8,9,10,11,12,16,20,24,28,32,36 circumferenceMeasuring tape | — |
Secondary
| Measure | Time frame |
|---|---|
| Muscle percentage Baseline, 1wk, 12 wks, 24 wks after treatment DEXA scan,Patient Improvement scale wk 0,4,8,12,16,20,24,28,32,36 percent improvement,Physician Improvement scale wk 0,4,8,12,16,20,24,28,32,36 percent improvement, Safety wk 0,1,2,3,4,5,6,7,8,9,10,11,12,16,20,24,28,32,36 Adverse event,Pain score wk 1,2,3,4,5,6,7,8,9,10,11 Visual analog scale | — |
Countries
Thailand
Contacts
Public ContactRungsima Wanitphakdeedecha
Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed